Augmentin Treatment Duration Recommendations for Respiratory Infections

General Recommendations

For most adult and pediatric respiratory tract infections, Augmentin (amoxicillin‑clavulanate) should be given for 7–14 days, with 10–14 days being the standard for chronic rhinosinusitis and lower respiratory tract infections. This recommendation is based on guideline consensus and multiple clinical studies. Strength of evidence: moderate‑to‑high (guideline‑based). 1

A 14‑day course of amoxicillin‑clavulanate 875 mg/125 mg twice daily is the established regimen. Strength of evidence: high (multiple randomized trials). 1
In these 14‑day trials, clinical cure rates reached 93 %, and bacteriologic eradication was comparable to alternative antibiotics. Strength of evidence: high. 1
Shorter 9‑day courses resulted in a markedly lower clinical cure rate (≈ 51 %) compared with the standard 14‑day regimen. Strength of evidence: moderate (single trial). 2

The recommended treatment duration is 7–10 days. Strength of evidence: moderate (guideline recommendation). 3
French national guidelines specify 7–10 days of therapy using amoxicillin‑clavulanate at 80 mg/kg/day for maxillary sinusitis. Strength of evidence: moderate (national guideline). 3

A 10‑day course is the standard for infants and toddlers with acute otitis media, reflecting evidence of higher relapse rates with shorter courses. Strength of evidence: moderate (clinical guideline). 4

Completing the full prescribed course is essential because bacteriologic eradication lags behind clinical improvement; premature discontinuation increases relapse risk. Strength of evidence: moderate (guideline). 1
Studies show a significant increase in clinical relapse (8 % vs 0 %) when treatment duration is insufficient. Strength of evidence: high (randomized data). 1

Extending therapy beyond 14 days for typical respiratory infections does not improve outcomes and raises the incidence of adverse effects, particularly diarrhea. Strength of evidence: moderate (clinical observation). 1
An exception applies when specific pathogens are identified that require longer therapy, as recommended by infectious disease guidelines. Strength of evidence: moderate (expert consensus). 5

Clinical response should be evaluated at 48–72 hours after initiation of therapy to confirm effectiveness. Strength of evidence: moderate (guideline). 4
Persistent or recurrent fever on day 5 signals treatment failure and warrants a change of antibiotic rather than simply extending the current regimen. Strength of evidence: moderate (expert recommendation). 7

Immunocompromised patients should receive the full 14‑day course regardless of infection severity, to ensure adequate bacterial eradication. Strength of evidence: moderate (guideline). 4
Children under 2 years with acute otitis media require a 10‑day regimen due to higher relapse rates with shorter courses. Strength of evidence: moderate (guideline). 4
Patients with recent antibiotic exposure (within 4–6 weeks) should be treated for 10–14 days because of the increased risk of resistant organisms. Strength of evidence: moderate (guideline). 4